Navigation Links
Avalere Health Data Finds Four-Tier System Growing Among Medicare Part D Plans
Date:4/15/2008

WASHINGTON, April 15 /PRNewswire/ -- Avalere Health today reminded consumers to pay close attention to all aspects of their Medicare prescription drug plan, including on which "tier" or group their medications are covered. Avalere data released from its proprietary DataFrame(R) database show that an overwhelming majority of Medicare health plans are now using a system that places some of the most expensive drugs in newly created fourth and fifth tiers. Drugs in the higher tiers can cost consumers significantly more money than a three tier, fixed co-payment system.

Consumers traditionally pay fixed amounts, or co-pays, when purchasing prescription drugs, and these co-pays are typically lumped into three groups: generics, preferred brands, and non-preferred brands. However, Medicare Part D drug plans have revolutionized the shape of the market by placing more expensive drugs into additional tiers. According to Avalere, 86% of all Medicare Part D plans use four (and sometimes five) tier plan structures, versus only 10% of commercial health plans.

"Health plans are trying to balance competing demands of access to medications and low cost, but the result is that patients with serious illnesses are paying more," said Dan Mendelson, president of Avalere Health. "It's a trend that's starting to push into the commercial world too."

Using its proprietary DataFrame database, which houses information about every Medicare drug plans' drug coverage and associated benefits, found that on average, Medicare Part D beneficiaries pay 25 percent to 35 percent of the cost of Tier 4 drugs compared with commercial plan beneficiaries who pay a fixed fee of about $71. Specialty drugs found in Tier 4 formularies can cost in excess of $600 per month.

"People with cancer, multiple sclerosis, hepatitis C, rheumatoid arthritis, and anemia should be paying very close attention to tiering in Medicare," said Mendelson.

Other facts released by Avalere:

-- Among Medicare's top 10 Part D plans, 9 use Tier 4 formularies;

-- The average co-payment for 4th Tier drugs in the Medicare community is

$70;

-- The average co-payment for 3rd Tier or non-preferred drugs in the

Medicare community is $40;

-- Medicare patients generally pay about $20 for preferred prescriptions,

and $10 for generic drugs.

For graphics you can use for media stories, please contact Kim Coghill at kcoghill@avalerehealth.net. For more information about Avalere's DataFrame database and the Medicare marketplace, contact Brian Bruen at bbruen@avalerehealth.net.


'/>"/>
SOURCE Avalere Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the Donut Hole
2. Texas Health Care Association: New Report on Long Term Care Workforce Spotlights Need to Boost Texas Medicaid Rates
3. Lake Hospital System Selected as Pilot Site for Health Information Literacy Research Project
4. New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements
5. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
6. Health Monitoring Systems Releases EpiCenter(TM)
7. Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008
8. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
9. Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief
10. Healthy Diabetic Bakery Products Launched Nationally
11. PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: